Carmine Gentile's Biography

Carmine Gentile, Lecturer in the School of Biomedical Engineering, University of Technology Sydney

Dr Carmine Gentile, PharmD/PhD, FAHA, is a Lecturer within the School of Biomedical Engineering at the University of Technology Sydney (UTS) and leads the Cardiovascular Regeneration Group both at UTS and at the University of Sydney. He received his BSc, MSc and PharmD at the University of Pisa, Italy and his PhD at the Medical University of South Carolina, Charleston, SC, USA, funded by a prestigious American Heart Association Fellowship. Since 2013 Dr Gentile has worked in Australia supported by several awards and grants, working within a multidisciplinary team with scientists, industry partners and clinicians to quickly translate his findings from bench to bedside. Dr Gentile is an internationally recognized expert in the field of 3D bioprinting and stem cell technologies and his more recent studies focus on novel molecular and cellular approaches to treat cardiovascular disease, including myocardial infarction and heart failure. These studies are based on the use of “mini-hearts” he developed as “bioinks” for human heart tissues. In 2016, he was invited as Visiting Research Fellow at Harvard Medical School, where he worked towards novel in vitro models using mini-hearts to study human heart physiology. His research received media attention and featured on ABC News (2016), ABC Catalyst (2017), Sydney TEDx (2018), Daily Telegraph (2019) and Channel 7News (2020).

Biofabrication of Heart Tissues using Cardiac Spheroids and 3D Bioprinting Technology for in vitro and in vivo Applications

Tuesday, 22 March 2022 at 13:30

Add to Calendar ▼2022-03-22 13:30:002022-03-22 14:30:00Europe/LondonBiofabrication of Heart Tissues using Cardiac Spheroids and 3D Bioprinting Technology for in vitro and in vivo ApplicationsBiofabrication and Biomanufacturing 2022 in BostonBostonSELECTBIOenquiries@selectbiosciences.com

3D bioprinting technology has emerged in the past 15 years as a tool for the bioengineering of human tissues and organs. In this approach, bioinks containing tissue-specific cells are deposited within permissive hydrogels to 3D bioprint viable and functional tissues. Dr Gentile’s team has developed cardiac bioinks by co-culturing cardiac cells in 3D as cardiac spheroids, which are then embedded in specialized hydrogels. 3D bioprinted heart tissues are viable, highly vascularized and contract synchronously when electrically paced. They are currently used for in vitro drug discovery and toxicity studies, for disease modeling of myocardial damage (i.e., heart attack in a Petri dish) and for cardiac regeneration purposes in vivo. Given their unique features in recapitulating the microenvironment typical of the human heart and its pathophysiology, 3D bioprinted heart tissues have the potential to be used to both prevent and treat cardiovascular disease in patients.

Add to Calendar ▼2022-03-21 00:00:002022-03-22 00:00:00Europe/LondonBiofabrication and Biomanufacturing 2022Biofabrication and Biomanufacturing 2022 in BostonBostonSELECTBIOenquiries@selectbiosciences.com

Conference Sponsors